<SEC-DOCUMENT>0001193125-16-669639.txt : 20160803
<SEC-HEADER>0001193125-16-669639.hdr.sgml : 20160803
<ACCEPTANCE-DATETIME>20160803123456
ACCESSION NUMBER:		0001193125-16-669639
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160729
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160803
DATE AS OF CHANGE:		20160803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INNOSPEC INC.
		CENTRAL INDEX KEY:			0001054905
		STANDARD INDUSTRIAL CLASSIFICATION:	CHEMICALS & ALLIED PRODUCTS [2800]
		IRS NUMBER:				981081725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13879
		FILM NUMBER:		161802994

	BUSINESS ADDRESS:	
		STREET 1:		8310 SOUTH VALLEY HIGHWAY
		STREET 2:		SUITE 350
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		303-566-0528

	MAIL ADDRESS:	
		STREET 1:		8310 SOUTH VALLEY HIGHWAY
		STREET 2:		SUITE 350
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OCTEL CORP
		DATE OF NAME CHANGE:	19980209
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d234278d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): July 29, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INNOSPEC INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>1-13879</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>98-0181725</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>8310 South Valley Highway </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 350 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Englewood,
Colorado, 80112 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (303) 792-5554 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</B> </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Entry into a Material Agreement. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Exclusivity and Put Option Agreement and Share and Asset Purchase
Agreement </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 29, 2016, Innospec International Ltd. (the &#147;Company&#148;), a company incorporated under the laws of England and Wales and a
wholly-owned subsidiary of Innospec Inc. (the &#147;Registrant&#148;), entered into an Exclusivity and Put Option Agreement, dated July 29, 2016 (the &#147;Put Option Agreement&#148;), with Huntsman Investments (Netherlands) B.V., a private company
with limited liability organized under the laws of the Netherlands (the &#147;Seller&#148;). The Put Option Agreement, together with the Share and Asset Purchase Agreement, to be entered into by and between the Company and Seller (the
&#147;SAPA,&#148; and, together with the Put Option Agreement, the &#147;Acquisition Agreements&#148;), attached as an exhibit to the Put Option Agreement, sets forth the terms of a commitment by the Company to the Seller to acquire the
Seller&#146;s European differentiated surfactants business (the &#147;Proposed Transaction&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Put Option Agreement, the Company
irrevocably undertakes to acquire the EDS Business (as defined in the SAPA) from the Seller, upon the terms and subject to certain conditions set out in the SAPA upon exercise by the Seller of the put option that Purchaser irrevocably granted to the
Seller pursuant to the Put Option Agreement. The Seller may exercise the put option by signing the SAPA and providing written notice during the period commencing on the date of the Put Option Agreement until the earlier of (a) the date falling five
(5) Business Days after the date on which an opinion is obtained, or deemed to be obtained, in accordance with applicable law from certain local works councils in respect of the Proposed Transaction and (b) January 15, 2017 (the &#147;Put Option
Exercise Period&#148;). Under the Put Option Agreement, the Seller has agreed that, during the Put Option Exercise Period, it shall not, and none of its affiliates shall, solicit or initiate any proposals from, discuss or negotiate with, provide any
non-public information to (including by way of access to electronic data rooms) any person (other than the Company) relating to the acquisition of the EDS Business or any similar transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the SAPA, the Proposed Transaction is expected to be accomplished through the Company&#146;s purchase of the EDS Shares (as defined in the SAPA) and the
EDS Assets (as defined in the SAPA) in addition to the Company&#146;s assumption or retention of the EDS Liabilities (as defined in the SAPA). The aggregate purchase price to be paid by the Company to the Seller will be approximately $225 million on
an enterprise value basis, subject to upward or downward adjustments for certain working capital items, inventory, net intercompany amounts, and certain adjustments related to employee matters, all as more fully set forth in the SAPA. The purchase
price will be estimated for closing purposes and then subsequently adjusted post-closing, in accordance with the SAPA. At the closing of the Proposed Transaction, the purchase price, as adjusted post-closing, is expected to be approximately $200
million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SAPA contains customary covenants of the Seller to continue to conduct the EDS Business as a going concern in the ordinary course and
preserve the EDS Business and its relationships with customers, key employees, suppliers, distributors and other third parties, in each case consistent with past practice, subject to certain exceptions. Additionally, the Seller has agreed to other
significant covenants including, among others: (a) providing access to properties and records, and maintaining confidentiality, (b) terminating certain intercompany arrangements, (c) terminating certain hedging arrangements, (d) withdrawal from
certain cash pooling arrangements, (e) obtaining releases for certain third-party guarantees and (f) certain non-competition covenants (for a period of five years) and non-solicitation covenants (for a period of two years). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SAPA also contains certain covenants of the Company, including, among others, (a) preparing certain Merger Control Filings (as defined in the SAPA) and
obtaining required consents from regulatory authorities and (b) certain non-solicitation covenants (for a period of two years). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Seller has agreed to
indemnify the Company, subject to certain exceptions and limitations set forth in the SAPA, with respect to retained liabilities and assets, certain environmental matters, and breaches of warranties and covenants, subject to certain deductions and
exceptions. The Company has agreed to indemnify the Seller, subject to certain exceptions and limitations, with respect to the EDS Liabilities (as defined in the SAPA). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Proposed Transaction is expected to close in the fourth quarter of 2016. Consummation of the Proposed Transaction under the terms of the SAPA is subject
to customary closing conditions, including, among others: (a) the making of certain Merger Control Filings and obtaining certain approvals, consents or clearances related thereto (the &#147;Competition Condition&#148;), (b) the absence of any
restraining and/or permanent governmental order or law which would restrain, enjoin or otherwise prohibit consummation of the Proposed Transaction, (c) the Seller and certain of its affiliates completing certain restructuring transactions in all
material respects and (d) the absence of any material adverse effect arising from the date of signing of the Put Option Agreement until satisfaction of the Competition Condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SAPA may be terminated under certain circumstances if the conditions to closing have not been satisfied by the Long Stop Time (as defined in the SAPA).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-right:2%; font-size:10pt; font-family:Times New Roman">The above description of the Acquisition Agreements does not purport to be complete, and is qualified in its entirety by reference to
the full text of the Acquisition Agreements, copies of which will be filed subsequently with the Securities and Exchange Commission. The Acquisition Agreements will be included to provide investors with information regarding their terms. Neither of
the Acquisition Agreements is intended to provide any other factual information about Seller, the Company, the Registrant or the EDS Entities (as defined in the SAPA). In particular, assertions embodied in warranties contained in the Acquisition
Agreements are qualified by information in confidential disclosures provided by Seller to the Company in connection with the signing of the Acquisition Agreements. These confidential disclosures contain information that modifies, qualifies and
creates exceptions to the warranties and certain covenants set forth in the Acquisition Agreements. Moreover, certain warranties in the Acquisition Agreements were used for purposes of allocating risk between the Company and Seller rather than
establishing matters as facts and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Accordingly, the warranties in the Acquisition Agreements should not be relied on as
characterizations of the actual state of facts about Seller, the Company, the Registrant or the EDS Entities. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Items </B></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><U>Debt Commitment</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with entering into the Put Option Agreement, the Registrant entered into
a commitment letter (the &#147;Commitment Letter&#148;) with Barclays Bank PLC, Credit Suisse AG, Lloyds Bank plc, National Westminster Bank plc, Wells Fargo Bank N.A. and U.S. Bank National Association (collectively, the &#147;Lenders&#148;) for a
commitment with respect to the debt financing required by the Company to consummate the Proposed Transactions. Pursuant to the Commitment Letter, the Lenders will act as mandated lead arrangers, and Lloyds Bank plc will act as facility agent for the
debt financing, on the terms and subject to the conditions set forth therein. The Commitment Letter contains conditions to funding of the debt financing customary for commitments of this type, including satisfaction of the conditions to the SAPA,
the absence of a material adverse change in the business, assets, liabilities, results of operations or conditions (financial or otherwise) of the EDS Entities, taken as a whole (which would entitle the Company not to complete the Proposed
Transactions in accordance with the terms of the SAPA), all necessary governmental, regulatory and corporate approvals to the Proposed Transaction being obtained, and other customary conditions. The Commitment Letter provides for a term loan
facility in the aggregate principal amount of up to $150,000,000. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><U>Press Release</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August 3, 2016, the Registrant issued a press release announcing the Company&#146;s
intention to acquire the Seller&#146;s European differentiated surfactants business, a copy of which is included as Exhibit 99.1 hereto and hereby incorporated by reference. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) The exhibits incorporated herein by reference or filed as part
of this report are set forth in the attached Exhibit Index. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release issued by Innospec Inc., dated August 3, 2016.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Innospec Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August 3, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David E. Williams</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David E. Williams</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">VP, General Counsel and CCO</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release issued by Innospec Inc., dated August 3, 2016</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d234278dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g234278nnnew1.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g234278new2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INNOSPEC COMMITS TO ACQUIRE EUROPEAN PERSONAL CARE AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HOME CARE BUSINESS FROM HUNTSMAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Signficant expansion to Innospec&#146;s Personal Care business with complementary products </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Brings substantial European market presence </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Creates much wider technology and asset base from which to serve customers globally </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Englewood, CO &#150; August 3, 2016 </B>&#150; Innospec Inc. (NASDAQ: IOSP) today announced that it commits to acquiring the European Personal Care and
Home Care business of Huntsman Corp. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The business is based in Belgium, and has manufacturing assets in France, Italy and Spain. With sales revenues of
around $230 million, the business employs approximately 430 people. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On a proforma basis the business has a full year outlook to generate $24m of EBITDA
(earnings before interest, tax, depreciation and amortization). The purchase price is expected to be $200m with an Enterprise Value of $225m as Huntsman will retain related accounts receivable and trade payables.&nbsp;Innospec will fund the purchase
through existing cash and additional debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patrick S. Williams, President and CEO of Innospec Inc said &#147; We have signalled for some time that we
have been seeking an appropriate acquisition in the Personal Care sector. Our preferred profile was always to add to our technology platforms, and grow our geographical presence. Our target is to significantly expand the range of products we can
offer to our customers in both Personal Care and Home Care.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bruce McDonald, President of Performance Chemicals at Innospec added&nbsp;&#147;The
Huntsman business has a well-established presence in Europe and the range of technologies is very complementary to the existing Innospec range. Together, we will now be competing in a much larger part of the sector. With substantial assets in Europe
from which to manufacture our existing and future products, the acquisition will form a springboard to continue Innospec&#146;s successful development of innovative technologies.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter R. Huntsman, President and CEO of Huntsman Corporation, commented: &#147;This proposed transaction is consistent with our strategic financial objectives
of increasing our cash flow generation, growing our downstream differentiated businesses and separating our titanium dioxide business.&nbsp;We plan to use the proceeds from this sale to repay our debt and strengthen our balance sheet.&nbsp;The
decoupling of our European surfactants business would allow us to concentrate our focus and grow businesses within our portfolio with greater long term strategic fit.&nbsp;Additional reshaping of Huntsman will occur soon, as we are actively working
towards a spin-off of our titanium dioxide, additives and textile effects businesses.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The acquisition process is subject to a period of
consultation with the employee representative bodies and clearance from the regulatory authorities. The transaction is expected to close early in the fourth quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patrick S. Williams added&nbsp;&#147;This helps us to deliver on our objective to build a larger Performance Chemicals segment which creates the balanced
portfolio of businesses we have outlined in our strategic plan&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Non-GAAP Financial Measures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information presented in this press release includes financial measures that are not calculated or presented in accordance with Generally Accepted
Accounting Principles in the United States (GAAP).&nbsp;These non-GAAP financial measures comprise EBITDA, income before income taxes excluding special items and net income excluding special items and related per share amounts.&nbsp;EBITDA is net
income per our consolidated financial statements adjusted for the exclusion of charges for interest expense, net, income taxes, depreciation, amortization and acquisition fair value adjustments.&nbsp;Income before income taxes, net income and
diluted EPS, excluding special items, per our consolidated financial statements are adjusted for the exclusion of foreign currency exchange (gains)/losses, amortization of acquired intangible assets, adjustment to fair value of contingent
consideration, acquisition-related costs and adjustment of income tax provisions.&nbsp;Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP financial measures are provided herein and in the schedules
below.&nbsp;The Company believes that such non-GAAP financial measures provide useful information to investors and may assist them in evaluating the Company&#146;s underlying performance and identifying operating trends.&nbsp;In addition, management
uses these non-GAAP financial measures internally to allocate resources and evaluate the performance of the Company&#146;s operations.&nbsp;While the Company believes that such measures are useful in evaluating the Company&#146;s performance,
investors should not consider them to be a substitute for financial measures prepared in accordance with GAAP.&nbsp;In addition, these non-GAAP financial measures may differ from similarly-titled non-GAAP financial measures used by other companies
and do not provide a comparable view of the Company&#146;s performance relative to other companies in similar industries.&nbsp;Management believes the most directly comparable GAAP financial measure is GAAP net income and has provided a
reconciliation of EBITDA and net income excluding special items, and related per share amounts, to GAAP net income herein and in the schedules below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Innospec Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Innospec Inc. is an international
specialty chemicals company with approximately 1300 employees in 20 countries. Innospec manufactures and supplies a wide range of specialty chemicals to markets in the Americas, Europe, the Middle East, Africa and Asia-Pacific.&nbsp;The Fuel
Specialties business specializes in manufacturing and supplying fuel additives that improve fuel efficiency, boost engine performance and reduce harmful emissions. Oilfield Services provides specialty chemicals to all elements of the oil &amp; gas
exploration and production industry.&nbsp;The Performance Chemicals business creates innovative technology-based solutions for our customers in the Personal Care market, focusing on skincare, haircare and suncare.&nbsp;Octane Additives produces
octane improvers to enhance gasoline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains certain &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995.&nbsp;All
statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements.&nbsp;Such forward-looking statements include statements (covered by words like &#147;expects,&#148;
&#147;estimates,&#148; &#147;anticipates,&#148; &#147;may,&#148; &#147;believes,&#148; &#147;feels&#148; or similar words or expressions), for example, which relate to earnings, growth potential, operating performance, events or developments that we
expect or anticipate will or may occur in the future.&nbsp;Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, and our actual performance or
results may differ materially from these forward-looking statements.&nbsp;Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec&#146;s
Annual Report on Form 10-K for the year ended December 31, 2015, and other reports filed with the U.S. Securities and Exchange Commission.&nbsp;You are urged to review our discussion of risks and uncertainties that could cause actual results to
differ from forward-looking statements under the heading &#147;Risk Factors&#148; in such reports.&nbsp;Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian Watt </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Innospec Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+44-151-355-3611 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian.Watt@innospecinc.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g234278new2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g234278new2.jpg
M_]C_X  02D9)1@ ! 0$ R #'  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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MUKVUCO()+*-)$>-RP7!+@Y.WT[BCP7\8?#?B_7%T>QBU"TO'#%$NH57>5!)
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MZZMDSB);GR$*E_0_/@?F3[5T?C[XH:%X)N[:ROX[N\OKE-\=M:1AF )(!.2
M,D$8Y/'2O)?#_CCQ+\+8[7POXXT 3:.I98W5024+98JP.R0 MG:<'GDBNC^*
M_@OQ))XPL_'O@5DO9HX48QA@[9 (#(K<,I4C@<]QG/ !W?@'XB6/C2YO+6UT
M[4=/NK%4:>.\C5,;LXQAB>W<"NLO+A;6TFN'5F6)&D(7J0!GCWKS;X1?$_\
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MM/FS!/*QYFS&6&<Y;\J^E_"MUJM[H%I<>(+*.PU*129K>-MRQG<<#.3VQWH
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g234278nnnew1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g234278nnnew1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ /P$$ P$1  (1 0,1 ?_$ +(   (" @,  P
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MKQ:5#7[-W#AHN@Z:+K-735=)RU=-U#HN&SENH55!PW63$JB*Z"I0,0Q1 2F
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M'_2$SA^2AR ..W.-XUCN4@$XR_,T3G>3)X97@-=[-\="VOB6NIX%1F@("'J
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M+VFR&GY8GHY+*[H$O(SU35&UZM=[I%_I<K*PU??.NR'L+<JW>T2[5P.4.XH
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M(SA12ESUE=M&3J ;QZ'Q(Q*"B5&Z#CY"BQU&O]XF *%..->W/=3E%WF8./\
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0.B(Z(CHB.B(Z(CHB.B+_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
